Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 14 Oct 2021
FDA accepts Regen-Cov (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19
14 October 2021 - European Medicines Agency also announced earlier this week it would review marketing authorisation application for the antibody ...
Posted by Michael Wonder on 14 Oct 2021
EMA starts rolling review of Evusheld (tixagevimab and cilgavimab)
14 October 2021 - EMA’s CHMP has started a rolling review of Evusheld (also known as AZD7442), a combination of ...
Posted by Michael Wonder on 14 Oct 2021
Novartis and the pan-Canadian Pharmaceutical Alliance complete negotiations for Zolgensma for the treatment of paediatric patients with spinal muscular atrophy
13 October 2021 - Novartis Pharmaceuticals Canada today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance for a ...
Posted by Michael Wonder on 14 Oct 2021
New Sarclisa (isatuximab) combination now approved by Health Canada for adults with relapsed and/or refractory multiple myeloma
13 October 2021 - The approval is based on data from the Phase 3 IKEMA trial. ...
Posted by Michael Wonder on 14 Oct 2021
Agilent receives FDA companion diagnostic approval for Ki-67 IHC MIB-1 pharmDx in high risk early breast cancer
13 October 2021 - Agilent Technologies today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as ...
Posted by Michael Wonder on 14 Oct 2021
Pharmacists opt out of third shot as doses of vaccine set to expire
14 October 2021 - The rollout of third doses of the COVID-19 vaccine to thousands of immunocompromised people has been ...
Posted by Michael Wonder on 14 Oct 2021
COVID-19 vaccine weekly safety report (14 October 2021)
14 October 2021 - To 10 October 2021, approximately 31 million vaccine doses have been given in Australia – 18 million ...
Posted by Michael Wonder on 13 Oct 2021
Why we can have both innovative drugs and lower drug prices
13 October 2021 - The debate in Congress over negotiating drug prices is based on a phony premise that higher prices ...
Posted by Michael Wonder on 13 Oct 2021
AstraZeneca COVID-19 vaccine will no longer be made in Australia
13 October 2021 - The AstraZeneca COVID-19 vaccine will no longer be manufactured in Australia due to the demand for ...
Posted by Michael Wonder on 13 Oct 2021
FDA approves pembrolizumab combination for the first-line treatment of cervical cancer
13 October 2021 - Today, the FDA approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for ...
Posted by Michael Wonder on 13 Oct 2021
SMC accepts Cabometyx/Opdivo combo for advanced kidney cancer patients
13 October 2021 - The SMC has recommended Cabometyx (cabozantinib) plus Opdivo (nivolumab) for use by via NHS Scotland for ...
Posted by Michael Wonder on 13 Oct 2021
Scotland is first country to offer free digital therapies to every adult
13 October 2021 - The Scottish Government has announced that all Scottish adults will now have access to "digital therapeutics" ...
Posted by Michael Wonder on 13 Oct 2021
EU may consider deal on Merck's COVID pill after approval procedure begins
12 October 2021 - The European Union may consider signing a supply deal with U.S. drugmaker Merck for its experimental ...
Posted by Michael Wonder on 13 Oct 2021
FDA approves abemaciclib with endocrine therapy for early breast cancer
13 October 2021 - On 12 October 2021, the FDA approved abemaciclib (Verzenio, Eli Lilly) with endocrine therapy (tamoxifen or an ...
Posted by Michael Wonder on 13 Oct 2021
MHRA backs Merck’s MET inhibitor Tepmetko
13 October 2021 - The UK MHRA has conditonally authorised Merck’s MET inhibitor Tepmetko (tepotinib) for the treatment of certain ...